Biosimilar Hulio Gets FDA Approval
The Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
General Rheumatology
Updated 2020 American College of Rheumatology Gout Management Guidelines
The American College of Rheumatology developed guidelines for the management of gout, including use of urate-lowering therapy, flare treatment, and lifestyle and medication recommendations.
Trial Investigating Ustekinumab for Systemic Lupus Erythematosus Discontinued
Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus.
First Treatment for Adult Onset Still Disease Gets FDA Approval
The FDA has approved Ilaris (canakinumab; Novartis) for the treatment of active Still disease, including adult-onset Still disease.
Recognizing Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a long-term autoimmune disorder that may affect the skin, joints, kidneys, brain and other organs. Although factors such as sunlight, certain drugs and viral infections are known to trigger SLE, the underlying cause is not fully understood. Because SLE is uncommon – it currently affects approximately 40 to 50 persons…
